Cure My Disease

Don't miss your cure!

 Log in / Sign up

Skin glow may predict inflammation in FMF patients

NCT ID NCT07439341

Knowledge-focused Sponsor: Bursa City Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether a painless skin scan can measure long-term inflammation in people with Familial Mediterranean Fever (FMF). Researchers will compare these skin measurements with a blood-based inflammation score called the CALLY index. The goal is to better understand ongoing low-level inflammation even when patients feel well.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients diagnosed with Familial Mediterranean Fever and age- and sex-matched healthy volunteers recruited from a single tertiary care center.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For FMF Patients: * Age between 18 and 65 years * Diagnosis of Familial Mediterranean Fever according to Tel-Hashomer criteria * At least 6 months of clinical follow-up * Available routine laboratory data (CRP, albumin, lymphocyte count) * Not in an acute FMF attack at the time of assessment * Ability to provide written informed consent For Healthy Controls: * Age between 18 and 65 years * No history of chronic inflammatory, autoimmune, metabolic, or renal disease * Ability to provide written informed consent Exclusion Criteria : * Diagnosis of diabetes mellitus * Chronic kidney disease stage 3 or higher * Active infection * Malignancy within the past 5 years * Dermatologic condition affecting the forearm measurement site * Use of high-dose antioxidant or vitamin supplementation within the past 3 months * Any condition that, in the opinion of the investigators, may interfere with study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Familial mediterranean fever are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyloidosis familial Mediterranean fever

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Familial mediterranean fever

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.